Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Japan's 1st GLP-1 Analogue Victoza: Novo Nordisk
February 1, 2010
- JSMI Recommends 29 More APIs for Switching to OTC Status
February 1, 2010
- Combination of ARB + Ca Blocker Rezaltas: Daiichi Sankyo
February 1, 2010
- Humira, Remicade to Be Excluded from DPC Payment When Used for Psoriasis
February 1, 2010
- Notification Issued for Proper Use of Afinitor
February 1, 2010
- Higher-Strength Metformin Preparation Metgluco Tab 250 mg: DSP
February 1, 2010
- Remicade for Psoriasis: MTPC
February 1, 2010
- Bendamustine Added to NCCN GLs as First-Line Therapy: SymBio
February 1, 2010
- Antidepressant Cymbalta: Shionogi
February 1, 2010
- Anti-Flu Agent Rapiacta Included in NHI Price List
February 1, 2010
- Greater Importance Put on Surgery in Insurance Coverage
February 1, 2010
- Xalacom for Glaucoma: Pfizer
February 1, 2010
- Korosho to Ask Companies to Comment on the Need for Listed Unapproved Drugs
February 1, 2010
- Cymbalta to Drive Shionogi's Business in Mid-Term: Ms Sawada
February 1, 2010
- Sugammadex for Reversal of Neuromuscular Blockade: Schering-Plough
February 1, 2010
- New Premium to Allow Chuikyo to Interfere with Company Management : Prof. Tsutsumi
February 1, 2010
- Takeda to More Actively Develop Business in Emerging Markets: President Hasegawa
February 1, 2010
- Anti-Emetic Aloxi: Taiho
February 1, 2010
- New Premium to Make Drugs More Liable to Re-Pricing: Mr Nishiyama
February 1, 2010
- Banyu, Schering-Plough to Copromote 7 Products in Preparation for Merger
February 1, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…